parallel randomized trial

SemVLCD

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

The Anabolic Effects of GLP-1 Agonism to Prevent Lean Muscle Losses During Very-low Calorie Diets (VLCDs) for Weight Loss

Type 2 diabetes (adults)NCT05606471S001656

Design

Randomized: 19
Start year: 2021
Treatment: 12 weeks, follow-up 12 weeks
Countries
Sponsor: University of Nottingham (not reported)
Eligibility: type 2 diabetes; BMI above 27

Conduct and analysis

Blinding: open label
Sequence generation: not reported
Allocation concealment: not reported
Outcome adjudication: not reported
Primary estimand: not stated
Analysis population
Missing data

Arms

Arm	Treatment	Background	Randomized
A1	Lifestyle intervention (randomized arm) Very low calorie diet only	lifestyle: intensive	7
A2	Semaglutide 1.0 mg subcutaneous once weekly Semaglutide 1 mg only	lifestyle: not reported	7
A3	Semaglutide 1.0 mg subcutaneous once weekly Semaglutide 1 mg plus very low calorie diet	800 kcal per day very low calorie diet; lifestyle: intensive	5

Results

8 adjudicated result lines, grouped by outcome. Open an outcome to see its values.

HbA1c change (2 lines; O01)

Week	Arm	Statistic	Estimate	SE or SD	95% CI	Events / N	Detail
12	A2	change	-11.3 mmol/mol				not stated; other; R0020431:Abstract
12	A3	change	-21.2 mmol/mol				not stated; other; R0020431:Abstract

Body weight change in kilograms (diabetes) (3 lines; O02)

Week	Arm	Statistic	Estimate	Detail
12	A1	change	-14.0 kg	not stated; other; R0020431:Abstract
12	A2	change	-6.4 kg	not stated; other; R0020431:Abstract
12	A3	change	-14.9 kg	not stated; other; R0020431:Abstract

Percent body weight change (3 lines; O10)

Week	Arm	Statistic	Estimate	Detail
12	A1	percent change	-11.6 percent	not stated; other; R0020431:Abstract
12	A2	percent change	-6.3 percent	not stated; other; R0020431:Abstract
12	A3	percent change	-14.2 percent	not stated; other; R0020431:Abstract